Abstract: An exhaust muffler, for longitudinal installation in a vehicle, includes a muffler housing (28) elongated in the direction of a longitudinal axis (G) of the housing. The muffler housing (28) has a housing jacket (30) and two front walls (32, 34), which are arranged, with respect to the direction of the longitudinal axis (G) of the housing, at spaced locations from one another. The front walls (32, 34) and the housing jacket (30) define a muffler interior space. At least one inlet pipe leads into the muffler interior space and at least one outlet pipe leads out of the muffler interior space. The housing jacket includes at least one predetermined deformation area (64, 66) including at least one wall area (68, 70), not parallel to the housing longitudinal axis (G), provided at the housing jacket (30).

Abstract: An insulin molecule comprises an Asp substitution at position B10, Glu at one or more of positions corresponding to A8, B28, and B29, and a halogenated phenylalanine at position B24. The analogue may optionally include (i) N-terminal deletion of one, two or three residues from the B chain, (ii) a mono-peptide or dipeptide C-terminal extension of the B-chain containing at least one acidic residue, and (iii) other modifications known in the art to enhance the stability of insulin. Formulations of the above analogues at successive strengths U-100 to U-1000 in soluble solutions at at least pH value in the range 7.0-8.0 in the absence or presence of zinc ions at a molar ratio of 0.00-0.10 zinc ions per insulin analogue monomer. A method of lowering the blood sugar level of a patient comprises administering a physiologically effective amount of the insulin to a patient.

Abstract: The present invention relates to an electrical heating device (25), comprising at least one electric heating resistance (27) and at least one heating resistance support (26). It is provided that the heating resistance (27) is disposed as a conductor strip at the heating resistor support (26), and that the heating resistance (27) comprises a stabilizing layer (28?, 28?) in addition to the heating resistance support (26).

Abstract: An insulin analog comprises a B-chain polypeptide incorporating a chlorinated phenylalanine. The chlorinated phenylalanine may be located at position B24. The chlorinated phenylalanine may be para-monochloro-phenylalanine. The analog may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analog. The chlorinated insulin analogs retain significant activity. A method of treating a patient comprises administering a physiologically effective amount of the insulin analog or a physiologically acceptable salt thereof to a patient. Chlorine substitution-based stabilization of insulin may reduce fibrillation and thereby enhance the treatment of diabetes mellitus in regions of the developing world lacking refrigeration.

Abstract: A method is disclosed for reducing the extent of myocardial cell damage or cell death arising from hypoxia or a loss, reduction or interruption in coronary blood flow comprising administering a pharmaceutical composition which includes riluzole or a pharmaceutically acceptable salt or derivative thereof. The method further discloses administering the pharmaceutical composition to reduce the incidence and severity of arrhythmias arising from the hypoxia or loss, reduction or interruption in coronary blood flow. The method also discloses treating a sequence of pathological events with the pharmaceutical composition wherein the sequence involves a cellular influx of sodium via persistent sodium channels, and the development of myocardial cellular damage or myocardial cellular death.

Abstract: An insulin analogue contains a foreshortened B-chain polypeptide lacking residues B1-B3 and optionally contains an additional substitution in the C-terminal B23-B30 segment of the B-chain. The insulin analogue lacking residues B1-B3 may contain substitutions at B28 and/or B29 that confer rapid action and optionally a non-standard substitution at B24. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. A method of semi-synthesis is provided using an unprotected octapeptide by means of modification of an endogenous tryptic site by non-standard amino-acid substitutions.

Abstract: Systems and methods for resolving fault detection in a control system is provided. The system includes an I/O module operably connected to a first, second, and third microcontroller for transmitting data. The first microcontroller is in an active state, i.e., in control, while the remaining controllers are in an idle state. The system further includes an event generator for generating an event indicative of a fault occurrence, and a means for detecting a fault event. The system also includes a means for reassigning a controller, wherein upon detection of a fault event in both the first and second controllers, the means for reassigning a controller changes the state of the third controller to active, leaving the remaining controllers idle or in a shutdown state, thereby effectively assigning control from the first controller to the third controller.

Abstract: A single-chain insulin analogue containing a basic side chain at position A8 (Arginine, Histidine, Lysine, or Ornithine), a basic side chain at position B29 (Arginine, Histidine, Lysine, or Ornithine), and a foreshortened C-domain of length 6-11 residues is provided. Residues C1 and C2 of the C-domain have a net negative charge of ?1 or ?2; C3 is chosen from a group consisting of Gly, Ala, Pro, or Ser; and the remaining C-domain segment is successively derived from the C-domain of IGF-II (RRSR, SRRSR, VSRRSR, RVSRRSR, or SRVSRRSR; SEQ ID NO: 13). A method of treating a patient with diabetes mellitus or obesity comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.

Abstract: A method and pharmaceutical composition are disclosed for treating, ameliorating and/or preventing one or more myocardial disorders in a mammalian heart caused by a myocardial hypoxic event and/or a loss, reduction or interruption in coronary blood flow such as may happen during or after events such as a heart attack, cardiac surgery including coronary artery bypass graft, or coronary artery or myocardial reperfusion. The myocardial disorders include myocardial arrhythmias, myocardial damage and myocardial cell death, and the subsequent loss of haemodynamic function. The myocardial disorders could be in progress or suspected of being in progress at the time of treatment or could be anticipated disorders being treated prophylactically. The method involves the step of administering an effective amount of the composition. The composition comprises as its active ingredient one or more compounds having myocardial persistent sodium channel blocking activity.

Abstract: An insulin analogue comprises an insulin B-chain polypeptide modified with an O-linked monosaccaride pyranoside adduct at the side chain of residue B27 or an O-linked monosaccaride pyranoside adduct at the side chain of residue B30, or both, where the positions are recited relative to human insulin. The monosaccaride may be a manopyranoside, an N-acetyl-galactopyranoside, or a glucopyranoside. The insulin analogue may additionally comprise containing a foreshortened B-chain polypeptide lacking residues B1-B3, an extension of 1 or 2 Glu residues on the carboxy terminal end of the B-chain polypeptide, an extension of ornithine at the carboxy-terminal end of the B-chain, the substitutions Lys at position B28 and Pro at position B29, an ornithine substitution at position B29, or combinations thereof. The analogue may be an analogue of a mammalian insulin, such as human insulin. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue.

Abstract: An insulin analogue comprises a B-chain polypeptide containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8, B28, and/or B29. A proinsulin analogue or single-chain insulin analogue containing a B domain containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8, B28, and/or B29. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. A method of semi-synthesis using an unprotected octapeptide by means of modification of an endogenous tryptic site by non-standard amino-acid substitutions.

Abstract: Catalyst compositions suitable for use in the exhaust gas recycle stream of an internal combustion engine are provided. Such catalyst compositions typically provide significant amounts of methane in addition to syngas. A reformer incorporating such a catalyst for use in an exhaust gas recycle portion of an internal combustion engine powertrain is described. A powertrain incorporating such a reformer, a method of increasing the octane rating of an exhaust gas recycle stream, and a method of operating an internal combustion engine using methane-assisted combustion are also described.

Abstract: A sensor arrangement for determining at least one measurand of a measuring medium includes at least one first sensor with a first sensing element used to record measured values of a first measurand of the measuring medium, a housing having a housing wall which surrounds a housing interior containing the first sensing element, wherein the housing interior contains a medium in particular, a liquid which has a predetermined value of the first measurand.

Abstract: Systems and methods for resolving fault detection in a control system is provided. The system includes an I/O module operably connected to a first, second, and third microcontroller for transmitting data. The first microcontroller is in an active state, i.e., in control, while the remaining controllers are in an idle state. The system further includes an event generator for generating an event indicative of a fault occurrence, and a means for detecting a fault event. The system also includes a means for reassigning a controller, wherein upon detection of a fault event in both the first and second controllers, the means for reassigning a controller changes the state of the third controller to active, leaving the remaining controllers idle or in a shutdown state, thereby effectively assigning control from the first controller to the third controller.

Abstract: The present invention provides rapid-acting insulin and insulin analogue formulations. The invention further provides delivery devices, particularly infusion sets, which allow for the rapid absorption of insulin and insulin analogues, as well as other active agents. Methods of using the insulin and insulin analogue formulations as well as the insulin delivery devices for treating subjects with diabetes mellitus are also provided.

Abstract: An exemplary power-electronic switching system has a plurality of switching units, wherein each switching unit includes a housing and at least one switching module which is arranged within the housing. A mounting unit has a holding apparatus, on which the housings of the switching units are arranged. The holding apparatus includes an insulation material for electrically insulating the holding apparatus from the housings of the switching units and the housings of the switching units from one another. The insulation material allows the housings of the switching units of the switching system to have different voltage potentials from one another and additionally can be realized in a simple and space-saving manner and easily be assembled. In addition, the housing of each switching unit includes a material for at least partially shielding an electric and magnetic field.

Abstract: An exhaust muffler for transverse installation in a vehicle includes a muffler housing (26) elongated in the direction of a housing longitudinal axis (G) with a housing jacket (28) and two front walls (30, 32). The two front walls (30, 32) are arranged at spaced locations from one another and define an interior (34) of the muffler with the housing jacket (28). At least one inlet pipe (36) leads into the interior (34) of the muffler and at least one outlet pipe (20) leads out of the interior (34) of the muffler. At least one front wall (30, 32) has at least one predetermined deformation area (50, 52).

Abstract: A single-chain insulin analog containing a basic side chain at position A8 (Arginine, Histidine, Lysine, or Ornithine), a basic side chain at position B29 (Arginine, Histidine, Lysine, or Ornithine), and a foreshortened C-domain of length 6-11 residues is provided. Residues C1 and C2 of the C-domain have a net negative charge of ?1 or ?2; C3 is chosen from a group consisting of Gly, Ala, Pro, or Ser; and the remaining C-domain segment is successively derived from the C-domain of IGF-II (RRSR (SEQ ID NO: 18), SRRSR (SEQ ID NO: 17), VSRRSR (SEQ ID NO: 16), RVSRRSR (SEQ ID NO: 15), or SRVSRRSR SEQ ID NO: 13). A method of treating a patient with diabetes mellitus or obesity comprises administering a physiologically effective amount of the insulin analog or a physiologically acceptable salt thereof to a patient.

Abstract: An insulin analog comprises a B-chain polypeptide containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8, B28, and/or B29. A proinsulin analog or single-chain insulin analog containing a B domain containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8, B28, and/or B29. The analog may be an analog of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analog is also provided. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analog or a physiologically acceptable salt thereof to a patient. A method of semi-synthesis using an unprotected octapeptide by means of modification of an endogenous tryptic site by non-standard amino-acid substitutions.

Abstract: The application concerns a support structure for power electronics, comprising a holder for the insertion of at least one power electronics module and an electrically conductive external geometry which surrounds the holder and has rounded corners and edges with a radius of curvature which is greater than a predetermined minimum radius.